This application claims the benefit of provisional application 60/724,265 filed Oct. 7, 2005. The entire disclosure of the provisional application is incorporated herein by reference. 
    
    
     This application incorporates by reference the contents of each of two duplicate CD-ROMs. Each CD-ROM contains an identical 186 kB file labeled “000040NC0 sequence listing” and containing the sequence listing for this application. Each CD-ROM also contains an identical 4.8 MB file labeled “ovarian.combinations” containing TABLE 1. The CD-ROMs were created on Oct. 06, 3006. 
     TECHNICAL FIELD OF THE INVENTION 
     This invention is related to the area of cancer diagnostics and therapeutics. In particular, it relates to aberrant methylation patterns of particular genes in cancers. 
     BACKGROUND OF THE INVENTION 
     DNA Methylation and its Role in Carcinogenesis 
     The information to make the cells of all living organisms is contained in their DNA. DNA is made up of a unique sequence of four bases: adenine (A), guanine (G), thymine (T) and cytosine (C). These bases are paired A to T and G to C on the two strands that form the DNA double helix. Strands of these pairs store information to make specific molecules grouped into regions called genes. Within each cell, there are processes that control what gene is turned on, or expressed, thus defining the unique function of the cell. One of these control mechanisms is provided by adding a methyl group onto cytosine (C). The methyl group tagged C can be written as mC. 
     DNA methylation plays an important role in determining whether some genes are expressed or not. By turning genes off that are not needed, DNA methylation functions as an essential control mechanism for the normal development and functioning of organisms. Conversely, abnormal DNA methylation is one of the mechanisms underlying the changes observed with aging and development of many cancers. 
     Historically, cancers have been linked to genetic changes caused by chromosomal mutations within the DNA. Mutations, hereditary or acquired, can lead to the loss of expression of genes critical for maintaining a healthy state. Evidence now indicates that a relatively large number of cancers originate, not from mutations, but from inappropriate DNA methylation. In many cases, hyper-methylation of DNA incorrectly switches off critical genes, such as tumor suppressor genes or DNA repair genes, allowing cancers to develop and progress. This non-mutational process for controlling gene expression is described as epigenetics. 
     DNA methylation is a chemical modification of DNA performed by enzymes called methyltransferases, in which a methyl group (m) is added to certain cytosines (C) of DNA. This non-mutational (epigenetic) process (mC) is a critical factor in gene expression regulation. See, J. G. Herman, Seminars in Cancer Biology, 9: 359-67, 1999. 
     Although the phenomenon of gene methylation has attracted the attention of cancer researchers for some time, its true role in the progression of human cancers is just now being recognized. In normal cells, methylation occurs predominantly in regions of DNA that have few CG base repeats, while CpG islands, regions of DNA that have long repeats of CG bases, remain non-methylated. Gene promoter regions that control protein expression are often CpG island-rich. Aberrant methylation of these normally non-methylated CpG islands in the promoter region causes transcriptional inactivation or silencing of certain tumor suppressor expression in human cancers. 
     Genes that are hypermethylated in tumor cells are strongly specific to the tissue of origin of the tumor. Molecular signatures of cancers of all types can be used to improve cancer detection, the assessment of cancer risk and response to therapy. Hypermethylated promoters events provide some of the most promising markers for such purposes. 
     Promoter Gene Hypermethylation: Promising Tumor Markers 
     Information regarding the hypermethylation of specific promoters of genes can be beneficial to diagnosis, prognosis and treatment of various cancers. Methylation of specific promoter regions can occur early and often in carcinogenesis making these markers ideal targets for cancer diagnostics. 
     Methylation patterns are tumor specific. Positive signals are always found in the same location of a gene. Real time PCR-based methods are highly sensitive, quantitative, and suitable for clinical use. DNA is stable and is found intact in readily available fluids (e.g., serum, sputum, stool and urine) and paraffin embedded tissues. Panels of pertinent gene markers may cover most human cancers. 
     Diagnosis 
     Key to improving the clinical outcome in patients with cancer is diagnosis at its earliest stage, while the cancer is still localized and readily treatable. The characteristics noted above provide the means for a more accurate screening and surveillance program by identifying higher-risk patients on a molecular basis. They could also provide justification for more definitive follow-up of patients who have molecular features, but not yet all the pathological or clinical features associated with malignancy. 
     Predicting Treatment Response 
     Information about how a cancer develops through molecular events could allow a clinician to predict more accurately how such a cancer is likely to respond to specific chemotherapeutic agents. In this way, a regimen based on knowledge of the tumor&#39;s chemosensitivity could be rationally designed. Studies have shown that hypermethylation of the MGMT promoter in glioma patients is indicative of a good response to therapy, greater overall survival, and a longer time to progression. 
     There is a continuing need in the art for new diagnostic markers and therapeutic targets for cancer to improve management of patient care. 
     SUMMARY OF THE INVENTION 
     According to a first embodiment of the invention a method is provided for identifying an ovarian cell as neoplastic or predisposed to neoplasia. Epigenetic silencing of at least one gene listed in Table 2 is detected in a test cell. The test cell is identified as neoplastic or predisposed to neoplasia based on the detection of epigenetic silencing. 
     In another embodiment of the invention a method is provided for reducing or inhibiting neoplastic growth of an ovarian cell which exhibits epigenetic silenced transcription of at least one gene associated with a cancer. Expression of a polypeptide encoded by the epigenetic silenced gene is restored in the cell by contacting the cell with a CpG dinucleotide demethylating agent. The gene is selected from those listed in Table 2. Unregulated growth of the cell is thereby reduced or inhibited. 
     Another aspect of the invention is a method of reducing or inhibiting neoplastic growth of an ovarian cell which exhibits epigenetic silenced transcription of at least one gene associated with a cancer. A polynucleotide encoding a polypeptide is introduced into an ovarian cell which exhibits epigenetic silenced transcription of at least one gene listed in Table 2. The polypeptide is encoded by the epigenetic-silenced gene. The polypeptide is thereby expressed in the cell thereby restoring expression of the polypeptide in the cell. 
     Still another aspect of the invention is a method of treating an ovarian cancer patient. A demethylating agent is administered to the patient in sufficient amounts to restore expression of a tumor-associated methylation-silenced gene selected from those listed in Table 2 in the patient&#39;s tumor. 
     An additional embodiment of the invention provides a method of treating an ovarian cancer patient. A polynucleotide encoding a polypeptide is administered to the patient. The polypeptide is encoded by a gene listed in Table 2. The polypeptide is expressed in the patient&#39;s tumor thereby restoring expression of the polypeptide in the tumor. 
     Yet another embodiment of the invention is a method for selecting a therapeutic strategy for treating an ovarian cancer patient. A gene selected from those listed in Table 2 whose expression in cancer cells of the patient is reactivated by a demethylating agent is identified. A therapeutic agent which reactivates expression of the gene is selected for treating the cancer patient. 
     A further embodiment of the invention is a kit for assessing methylation in an ovarian cell sample. The kit comprises certain components in a package. One component is a reagent that (a) modifies methylated cytosine residues but not non-methylated cytosine residues, or that (b) modifies non-methylated cytosine residues but not methylated cytosine residues. A second component is a pair of oligonucleotide primers that specifically hybridizes under amplification conditions to a region of a gene selected from those listed in Table 2. The region is within about 1 kb of said gene&#39;s transcription start site. 
     These and other embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with tools and methods for detection, diagnosis, therapy, and drug selection pertaining to neoplastic cells and cancers. 
     BRIEF DESCRIPTION OF THE TABLES 
     Table 1 lists combinations of 2, 3, 4, 5, and 6 genes which are hypermethylated in ovarian cancer cells. 
     Table 2 lists genes and splice variants which are hypermethylated in ovarian cancer cells. Accession numbers for the encoded proteins and nucleic acids are shown. 
     Table 3 accompanies the Sequence Listing. 
     Table 4 shows primers and annealing temperatures used for MSP reactions 
     Table 5 shows promoter hypermethylation results of tubae standard genes. 
     Table 6 shows MSP methascore results and the SCA grading for each of the subjects. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The inventors have discovered a set of genes whose transcription is epigenetically silenced in ovarian cancers. These genes include those encoding TTKTTK protein kinase, CGI-38 brain specific protein, DUSP4 dual specificity phosphatase 4, RUNX3 runt-related transcription factor 3, TRIP13 thyroid hormone receptor interactor 13, TK1 thymidine kinase 1 (soluble), SMPD2 sphingomyelin phosphodiesterase 2 (neutral membrane; neutral sphingomyelinase), MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2, MSH2 mutS homolog 2, nonpolyposis type 1 colon cancer, BARD1 BRCA1 associated RING domain 1, INPP4B inositol polyphosphate-4-phosphatase, type II (105 kDa), NDP Norrie disease (pseudoglioma), TM4SF11 transmembrane 4 superfamily member 11 (plasmolipin), HPSE heparanase, C11orf2 chromosome 11 open reading frame 2, DEKDEK oncogene (DNA binding), ASK activator of S phase kinase, POLR3D polymerase (RNA) III (DNA directed) polypeptide D (44 kDa), HEC highly expressed in cancer, rich in leucine heptad repeats, ACTN1 actinin (alpha 1), FANCG Fanconi anemia (complementation group G), HDGF hepatoma-derived growth factor (high-mobility group protein 1-like), and TNFRSF10B tumor necrosis factor receptor superfamily (member 10b). All of the identified genes are shown in Table 2. 
     
       
         
               
               
               
               
             
           
               
                   
                 TABLE 2 
               
               
                   
                   
               
             
             
               
                   
                  1. TTK 
                 NP_003309 
                 NM_003318 
               
               
                   
                  2. CGI-38 
                 NP_057048, 
                 NM_015964.2, 
               
               
                   
                   
                 NP_057224 
                 NM_016140.2 
               
               
                   
                  3. DUSP4 
                 NP_476499, 
                 NM_057158.2, 
               
               
                   
                   
                 NP_001385 
                 NM_001394.5 
               
               
                   
                  4. RUNX3 
                 NP_004341 
                 NM_004350.1 
               
               
                   
                  5. TRIP13 
                 NP_004228 
                 NM_004237.2 
               
               
                   
                  6. TK1 
                 NP_003249 
                 NM_003258.1 
               
               
                   
                  7. SMPD2 
                 NP_003071 
                 NM_003080.1 
               
               
                   
                  8. MYBL2 
                 NP_002457 
                 NM_002466.2 
               
               
                   
                  9. MSH2 
                 NP_000242 
                 NM_000251.1 
               
               
                   
                 10. BARD1 
                 NP_000456 
                 NM_000465.1 
               
               
                   
                 11. INPP4B 
                 NP_003857 
                 NM_003866.1 
               
               
                   
                 12. NDP 
                 NP_000257 
                 NM_000266.1 
               
               
                   
                 13. TM4SF11 
                 NP_057077 
                 NM_015993.1 
               
               
                   
                 14. HPSE 
                 NP_006656 
                 NM_006665.2 
               
               
                   
                 15. C11orf2 
                 NP_037397 
                 NM_013265.2 
               
               
                   
                 16. DEK 
                 NP_003463 
                 NM_003472.2 
               
               
                   
                 17. ASK 
                 NP_006707 
                 NM_006716.3 
               
               
                   
                 18. POLR3D 
                 NP_001713, 
                 NM_001722.2 
               
               
                   
                 19. HEC 
                 NP_006092 
                 NM_006101.1 
               
               
                   
                 20. ACTN1 
                 NP_001093 
                 NM_001102.2 
               
               
                   
                 21. FANCG 
                 NP_004620 
                 NM_004629.1 
               
               
                   
                 22. HDGF 
                 NP_004485 
                 NM_004494.1 
               
               
                   
                 23. TNFRSF10B 
                 NP_003833, 
                 NM_003842.3, 
               
               
                   
                   
                 NP_671716 
                 NM_147187.1 
               
               
                   
                   
               
             
          
         
       
     
     Epigenetic silencing of a gene can be determined by any method known in the art. One method is to determine that a gene which is expressed in normal cells is less expressed or not expressed in tumor cells. This method does not, on its own, however, indicate that the silencing is epigenetic, as the mechanism of the silencing could be genetic, for example, by somatic mutation. One method to determine that the silencing is epigenetic is to treat with a reagent, such as DAC (5′-deazacytidine) and observe that the silencing is reversed, i.e., that the expression of the gene is reactivated or restored. Another means to determine epigenetic silencing is to determine the presence of methylated CpG dinucleotide motifs in the silenced gene. Typically these reside near the transcription start site, for example, within about 1 kbp, within about 750 bp, or within about 500 bp. 
     Expression of a gene can be assessed using any means known in the art. Either mRNA or protein can be measured. Methods employing hybridization to nucleic acid probes can be employed for measuring specific mRNAs. Such methods include using nucleic acid probe arrays and using Northern blots. Messenger RNA can also be assessed using amplification techniques, such as RT-PCR. Specific proteins can be assessed using any convenient method. Most such methods will employ antibodies which are specific for the particular protein. The sequences of the mRNA (cDNA) and proteins of the markers of the present invention are provided in the sequence listing. 
     Methylation-sensitive restriction endonucleases can be used to detect methylated CpG dinucleotide motifs. Such endonucleases may either preferentially cleave methylated recognition sites relative to non-methylated recognition sites or preferentially cleave non-methylated relative to methylated recognition sites. Examples of the former are Acc III, Ban I, BstN I, Msp I, and Xma I. Examples of the latter are Acc II, Ava I, BssH II, BstU I, Hpa II, and Not I. Alternatively, chemical reagents can be used which selectively modify either the methylated or non-methylated form of CpG dinucleotide motifs. 
     Modified products can be detected directly, or after a further reaction which creates products which are easily distinguishable. Means which detect altered size and/or charge can be used to detect modified products, including but not limited to electrophoresis, chromatography, and mass spectrometry. Examples of such chemical reagents for selective modification include hydrazine and bisulfite ions. Hydrazine-modified DNA can be treated with piperidine to cleave it. Bisulfite ion-treated DNA can be treated with alkali. 
     One way to distinguish between modified and unmodified DNA is to hybridize oligonucleotide primers which specifically bind to one form or the other of the DNA. After hybridization, an amplification reaction can be performed and amplification products assayed. The presence of an amplification product indicates that a sample hybridized to the primer. The specificity of the primer indicates whether the DNA had been modified or not, which in turn indicates whether the DNA had been methylated or not. For example, bisulfite ions modify non-methylated cytosine bases, changing them to uracil bases. Uracil bases hybridize to adenine bases under hybridization conditions. Thus an oligonucleotide primer which comprises adenine bases in place of guanine bases would hybridize to the bisulfite-modified DNA, whereas an oligonucleotide primer containing the guanine bases would hybridize to the non-modified (methylated) cytosine residues in the DNA. Amplification using a DNA polymerase and a second primer yield amplification products which can be readily observed. Such a method is termed MSP ( M ethylation  S pecific  P CR). The amplification products can be optionally hybridized to specific oligonucleotide probes which may also be specific for certain products. Alternatively, oligonucleotide probes can be used which will hybridize to amplification products from both modified and nonmodified DNA. 
     Another way to distinguish between modified and nonmodified DNA is to use oligonucleotide probes which may also be specific for certain products. Such probes can be hybridized directly to modified DNA or to amplification products of modified DNA. Oligonucleotide probes can be labeled using any detection system known in the art. These include but are not limited to fluorescent moieties, radioisotope labeled moieties, bioluminescent moieties, luminescent moieties, chemiluminescent moieties, enzymes, substrates, receptors, or ligands. 
     Test cells for diagnostic, prognostic, or personalized medicine uses can be obtained from surgical samples, such as biopsies or fine needle aspirates, from paraffin embedded tissues, from a body fluid such as bone marrow, blood, serum, lymph, cerebrospinal fluid, saliva, sputum, stool, urine, or semen. Such sources are not meant to be exhaustive, but rather exemplary. 
     Demethylating agents can be contacted with cells in vitro or in vivo for the purpose of restoring normal gene expression to the cell. Suitable demethylating agents include, but are not limited to 5-aza-2′-deoxycytidine, 5-aza-cytidine, Zebularine, procaine, and L-ethionine. This reaction may be used for diagnosis, for determining predisposition, and for determining suitable therapeutic regimes. 
     An alternative way to restore epigenetically silenced gene expression is to introduce a non-methylated polynucleotide into an ovarian cell, so that it will be expressed in the cell. Various gene therapy vectors and vehicles are known in the art and any can be used as is suitable for a particular situation. Certain vectors are suitable for short term expression and certain vectors are suitable for prolonged expression. Certain vectors are trophic for certain organs and these can be used as is appropriate in the particular situation. Vectors may be viral or non-viral. The polynucleotide can, but need not, be contained in a vector, for example, a viral vector, and can be formulated, for example, in a matrix such as a liposome, or a microbubble. The polynucleotide can be introduced into an ovarian cell by administering the polynucleotide to the subject such that it contacts the cell and is taken up by the cell and the encoded polypeptide expressed. Suitable polynucleotides are provided in the sequence listing in the odd numbered sequences of SEQ ID NO: 1-51. Polynucleotides encoding the polypeptides shown in even numbered sequences of SEQ ID NO: 2-52 can also be used. Preferably the specific polynucleotide will be one for which the patient has been tested and been found to carry a silenced version. 
     Marker proteins and genes as set forth in Table 2 encompass not only the particular sequences found in the publicly available database entries which are listed (as of today) and in the Sequence Listing, but also encompass variants of these sequences, including allelic variants. Variant sequences have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to sequences in the database entries or Sequence Listing. Variant forms of the encoded proteins may comprise post-translational modifications, may result from alternatively spliced messages, etc. Any variant within the parameters described may be used if it is subject to epigenetic silencing in an ovarian cancer patient&#39;s tumor. Computer programs for determining percent identity are available in the art, including the Basic Local Alignment Search Tool (BLAST) available from the National Center for Biotechnology Information. 
     Cells exhibiting methylation silenced gene expression can be contacted with a demethylating agent in vivo by administering the agent to a subject. Where convenient, the demethylating agent can be administered using, for example, a catheterization procedure, at or near the site of the cells exhibiting unregulated growth in the subject, or into a blood vessel in which the blood is flowing to the site of the cells. Similarly, where an organ, or portion thereof, to be treated can be isolated by a shunt procedure, the agent can be administered via the shunt, thus substantially providing the agent to the site containing the cells. The agent also can be administered systemically or via other routes known in the art. 
     The polynucleotide can include, in addition to polypeptide coding sequence, operatively linked transcriptional regulatory elements, translational regulatory elements, and the like, and can be in the form of a naked DNA molecule, which can be contained in a vector, or can be formulated in a matrix such as a liposome or microbubbles that facilitates entry of the polynucleotide into the particular cell. The term “operatively linked” refers to two or more molecules that are positioned with respect to each other such that they act as a single unit and affect a function attributable to one or both molecules or a combination thereof. A polynucleotide sequence encoding a desired polypeptide can be operatively linked to a regulatory element, in which case the regulatory element confers its regulatory effect on the polynucleotide similar to the way in which the regulatory element would effect a polynucleotide sequence with which it normally is associated within a cell. 
     The polynucleotide encoding the desired polypeptide to be administered to a mammal or a human or to be contacted with an ovarian cell may contain a promoter sequence, which can provide constitutive or, if desired, inducible or tissue specific or developmental stage specific expression of the polynucleotide, a poly-A recognition sequence, and a ribosome recognition site or internal ribosome entry site, or other regulatory elements such as an enhancer, which can be tissue specific. The vector also may contain elements required for replication in a prokaryotic or eukaryotic host system or both, as desired. Such vectors, which include plasmid vectors and viral vectors such as bacteriophage, baculovirus, retrovirus, lentivirus, adenovirus, vaccinia virus, semliki forest virus and adeno-associated virus vectors, are well known and can be purchased from a commercial source (Promega, Madison, Wis.; Stratagene, La Jolla, Calif.; GIBCO/BRL, Gaithersburg, Md.) or can be constructed by one skilled in the art (see, for example, Meth. Enzymol., Vol. 185, Goeddel, ed. (Academic Press, Inc., 1990); Jolly, Canc. Gene Ther. 1:51-64, 1994; Flotte, J. Bioenerg. Biomemb. 25:37-42, 1993; Kirshenbaum et al., J. Clin. Invest. 92:381-387, 1993; each of which is incorporated herein by reference). 
     A tetracycline (tet) inducible promoter can be used for driving expression of a polynucleotide encoding a desired polypeptide. Upon administration of tetracycline, or a tetracycline analog, to a subject containing a polynucleotide operatively linked to a tet inducible promoter, expression of the encoded polypeptide is induced. The polynucleotide alternatively can be operatively linked to tissue specific regulatory element, for example, a liver cell specific regulatory element such as an α.-fetoprotein promoter (Kanai et al., Cancer Res. 57:461-465, 1997; He et al., J. Exp. Clin. Cancer Res. 19:183-187, 2000) or an albumin promoter (Power et al., Biochem. Biophys. Res. Comm. 203:1447-1456, 1994; Kuriyama et al., Int. J. Cancer 71:470-475, 1997); a muscle cell specific regulatory element such as a myoglobin promoter (Devlin et al., J. Biol. Chem. 264:13896-13901, 1989; Yan et al., J. Biol. Chem. 276:17361-17366, 2001); a prostate cell specific regulatory element such as the PSA promoter (Schuur et al., J. Biol. Chem. 271:7043-7051, 1996; Latham et al., Cancer Res. 60:334-341, 2000); a pancreatic cell specific regulatory element such as the elastase promoter (Ornitz et al., Nature 313:600-602, 1985; Swift et al., Genes Devel. 3:687-696, 1989); a leukocyte specific regulatory element such as the leukosialin (CD43) promoter (Shelley et al., Biochem. J. 270:569-576, 1990; Kudo and Fukuda, J. Biol. Chem. 270:13298-13302, 1995); or the like, such that expression of the polypeptide is restricted to particular cell in an individual, or to particular cells in a mixed population of cells in culture, for example, an organ culture. Regulatory elements, including tissue specific regulatory elements, many of which are commercially available, are well known in the art (see, for example, InvivoGen; San Diego, Calif.). 
     Viral expression vectors can be used for introducing a polynucleotide into an ovarian cell, particularly an ovarian cell in a subject. Viral vectors provide the advantage that they can infect host cells with relatively high efficiency and can infect specific cell types. For example, a polynucleotide encoding a desired polypeptide can be cloned into a baculovirus vector, which then can be used to infect an insect host cell, thereby providing a means to produce large amounts of the encoded polypeptide. Viral vectors have been developed for use in particular host systems, particularly mammalian systems and include, for example, retroviral vectors, other lentivirus vectors such as those based on the human immunodeficiency virus (HIV), adenovirus vectors, adeno-associated virus vectors, herpesvirus vectors, hepatitis virus vectors, vaccinia virus vectors, and the like (see Miller and Rosman, BioTechniques 7:980-990, 1992; Anderson et al., Nature 392:25-30 Suppl., 1998; Verma and Somia, Nature 389:239-242, 1997; Wilson, New Engl. J. Med. 334:1185-1187 (1996), each of which is incorporated herein by reference). 
     A polynucleotide, which can optionally be contained in a vector, can be introduced into an ovarian cell by any of a variety of methods known in the art (Sambrook et al., supra, 1989; Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1987, and supplements through 1995), each of which is incorporated herein by reference). Such methods include, for example, transfection, lipofection, microinjection, electroporation and, with viral vectors, infection; and can include the use of liposomes, microemulsions or the like, which can facilitate introduction of the polynucleotide into the cell and can protect the polynucleotide from degradation prior to its introduction into the cell. A particularly useful method comprises incorporating the polynucleotide into microbubbles, which can be injected into the circulation. An ultrasound source can be positioned such that ultrasound is transmitted to the target organ or tissue, whereby circulating microbubbles containing the polynucleotide are disrupted at the site of the target due to the ultrasound, thus providing the polynucleotide at the site of the target. The selection of a particular method will depend, for example, on the cell into which the polynucleotide is to be introduced, as well as whether the cell is in culture or in situ in a body. 
     Introduction of a polynucleotide into an ovarian cell by infection with a viral vector can efficiently introduce the nucleic acid molecule into an ovarian cell. Moreover, viruses are very specialized and can be selected as vectors based on an ability to infect and propagate in one or a few specific cell types. Thus, their natural specificity can be used to target the nucleic acid molecule contained in the vector to specific cell types. A vector based on an HIV can be used to infect T cells, a vector based on an adenovirus can be used, for example, to infect respiratory epithelial cells, a vector based on a herpesvirus can be used to infect neuronal cells, and the like. Other vectors, such as adeno-associated viruses can have greater host cell range and, therefore, can be used to infect various cell types, although viral or non-viral vectors also can be modified with specific receptors or ligands to alter target specificity through receptor mediated events. A polynucleotide of the invention, or a vector containing the polynucleotide can be contained in a cell, for example, a host cell, which allows propagation of a vector containing the polynucleotide, or a helper cell, which allows packaging of a viral vector containing the polynucleotide. The polynucleotide can be transiently contained in the cell, or can be stably maintained due, for example, to integration into the cell genome. 
     A polypeptide according to any of even numbered sequences between SEQ ID NO: 2-52 or a variant thereof, as discussed above, can be administered directly to the site of a cell exhibiting unregulated growth in the subject. The polypeptide can be produced and isolated, and formulated as desired, using methods as disclosed herein, and can be contacted with the cell such that the polypeptide can cross the cell membrane of the target cells. The polypeptide may be provided as part of a fusion protein, which includes a peptide or polypeptide component that facilitates transport across cell membranes. For example, a human immunodeficiency virus (HIV) TAT protein transduction domain or a nuclear localization domain may be fused to the marker of interest. The administered polypeptide can be formulated in a matrix that facilitates entry of the polypeptide into a cell. 
     An agent such as a demethylating agent, a polynucleotide, or a polypeptide is typically formulated in a composition suitable for administration to the subject. Thus, the invention provides compositions containing an agent that is useful for restoring regulated growth to a cell exhibiting unregulated growth due to methylation silenced transcription of one or more genes. The agents are useful as medicaments for treating a subject suffering from a pathological condition associated with such unregulated growth. Such medicaments generally include a carrier. Acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil or injectable organic esters. An acceptable carrier can contain physiologically acceptable compounds that act, for example, to stabilize or to increase the absorption of the conjugate. Such physiologically acceptable compounds include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. One skilled in the art would know or readily be able to determine an acceptable carrier, including a physiologically acceptable compound. The nature of the carrier depends on the physico-chemical characteristics of the therapeutic agent and on the route of administration of the composition. Administration of therapeutic agents or medicaments can be by the oral route or parenterally such as intravenously, intramuscularly, subcutaneously, transdermally, intranasally, intrabronchially, vaginally, rectally, intratumorally, or other such method known in the art. The pharmaceutical composition also can contain one more additional therapeutic agents. 
     The therapeutic agents can be incorporated within an encapsulating material such as into an oil-in-water emulsion, a microemulsion, micelle, mixed micelle, liposome, microsphere, microbubbles or other polymer matrix (see, for example, Gregoriadis, Liposome Technology, Vol. 1 (CRC Press, Boca Raton, Fla. 1984); Fraley, et al., Trends Biochem. Sci., 6:77 (1981), each of which is incorporated herein by reference). Liposomes, for example, which consist of phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer. “Stealth” liposomes (see, for example, U.S. Pat. Nos. 5,882,679; 5,395,619; and 5,225,212, each of which is incorporated herein by reference) are an example of such encapsulating materials particularly useful for preparing a composition useful in a method of the invention, and other “masked” liposomes similarly can be used, such liposomes extending the time that the therapeutic agent remain in the circulation. Cationic liposomes, for example, also can be modified with specific receptors or ligands (Morishita et al., J. Clin. Invest., 91:2580-2585 (1993), which is incorporated herein by reference). In addition, a polynucleotide agent can be introduced into a cell using, for example, adenovirus-polylysine DNA complexes (see, for example, Michael et al., J. Biol. Chem. 268:6866-6869 (1993), which is incorporated herein by reference). 
     The route of administration of the composition containing the therapeutic agent will depend, in part, on the chemical structure of the molecule. Polypeptides and polynucleotides, for example, are not efficiently delivered orally because they can be degraded in the digestive tract. However, methods for chemically modifying polypeptides, for example, to render them less susceptible to degradation by endogenous proteases or more absorbable through the alimentary tract may be used (see, for example, Blondelle et al., supra, 1995; Ecker and Crook, supra, 1995). 
     The total amount of an agent to be administered in practicing a method of the invention can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or can be administered using a fractionated treatment protocol, in which multiple doses are administered over a prolonged period of time. One skilled in the art would know that the amount of the composition to treat a pathologic condition in a subject depends on many factors including the age and general health of the subject as well as the route of administration and the number of treatments to be administered. In view of these factors, the skilled artisan would adjust the particular dose as necessary. In general, the formulation of the composition and the routes and frequency of administration are determined, initially, using Phase I and Phase II clinical trials. 
     The composition can be formulated for oral formulation, such as a tablet, or a solution or suspension form; or can comprise an admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications, and can be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, or other form suitable for use. The carriers, in addition to those disclosed above, can include glucose, lactose, mannose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening or coloring agents and perfumes can be used, for example a stabilizing dry agent such as triulose (see, for example, U.S. Pat. No. 5,314,695). 
     Although accuracy and sensitivity may be achieved by using a combination of markers, such as 5 or 6 markers, practical considerations may dictate use of smaller combinations. Any combination of markers for ovarian cancer may be used which comprises 2, 3, 4, or 5 markers. Each of the combinations for two through six markers are listed in Table 1 found on CD-ROM. Other combinations of more than six markers can be readily envisioned given the specific disclosures of individual markers provided herein. Any number of markers from 1 to 23 can be used, inclusive. 
     Kits according to the present invention are assemblages of reagents for testing methylation. They are typically in a package which contains all elements, optionally including instructions. The package may be divided so that components are not mixed until desired. Components may be in different physical states. For example, some components may be lyophilized and some in aqueous solution. Some may be frozen. Individual components may be separately packaged within the kit. The kit may contain reagents, as described above for differentially modifying methylated and non-methylated cytosine residues. Desirably the kit will contain oligonucleotide primers which specifically hybridize to regions within 1 kb of the transcription start sites of the genes identified in Table 2. Typically the kit will contain both a forward and a reverse primer for a single gene. Specific hybridization typically is accomplished by a primer having at least 12, 14, 16, 18, or 20 contiguous nucleotides which are complementary to the target template. Often the primer will be 100% identical to the target template. If there is a sufficient region of complementarity, e.g., 12, 15, 18, or 20 nucleotides, then the primer may also contain additional nucleotide residues that do not interfere with hybridization but may be useful for other manipulations. Exemplary of such other residues may be sites for restriction endonuclease cleavage, for ligand binding or for factor binding or linkers. The oligonucleotide primers may or may not be such that they are specific for modified methylated residues. The kit may optionally contain oligonucleotide probes. The probes may be specific for sequences containing modified methylated residues or for sequences containing non-methylated residues. Like the primers as described above, specific hybridization is accomplished by having a sufficient region of complementarity to the target. The kit may optionally contain reagents for modifying methylated cytosine residues. The kit may also contain components for performing amplification, such as a DNA polymerase and deoxyribonucleotides. Means of detection may also be provided in the kit, including detectable labels on primers or probes. Kits may also contain reagents for detecting gene expression for one of the markers of the present invention (Table 2). Such reagents may include probes, primers, or antibodies, for example. In the case of enzymes or ligands, substrates or binding partners may be sued to assess the presence of the marker. 
     In one aspect of the invention, the maker gene(s) is contacted with hydrazine, which modifies cytosine residues, but not methylated cytosine residues, then the hydrazine treated gene sequence is contacted with a reagent such as piperidine, which cleaves the nucleic acid molecule at hydrazine modified cytosine residues, thereby generating a product comprising fragments. By separating the fragments according to molecular weight, using, for example, an electrophoretic, chromatographic, or mass spectrographic method, and comparing the separation pattern with that of a similarly treated corresponding non-methylated gene sequence, gaps are apparent at positions in the test gene that contained methylated cytosine residues. The presence of gaps is indicative of methylation of a cytosine residue in the CpG dinucleotide in the target gene of the test cell. 
     Bisulfite ions, for example, sodium bisulfite, convert non-methylated cytosine residues to bisulfite modified cytosine residues. The bisulfite ion treated gene sequence can be exposed to alkaline conditions, which convert bisulfite modified cytosine residues to uracil residues. Sodium bisulfite reacts readily with the 5,6-double bond of cytosine (but poorly with methylated cytosine) to form a sulfonated cytosine reaction intermediate that is susceptible to deamination, giving rise to a sulfonated uracil. The sulfonate group can be removed by exposure to alkaline conditions, resulting in the formation of uracil. The DNA can be amplified, for example, by PCR, and sequenced to determine whether CpG sites are methylated in the DNA of the sample. Uracil is recognized as a thymine by Taq polymerase and, upon PCR, the resultant product contains cytosine only at the position where 5-methylcytosine was present in the starting template DNA. One can compare the amount or distribution of uracil residues in the bisulfite ion treated gene sequence of the test cell with a similarly treated corresponding non-methylated gene sequence. A decrease in the amount or distribution of uracil residues in the gene from the test cell indicates methylation of cytosine residues in CpG dinucleotides in the gene of the test cell. The amount or distribution of uracil residues also can be detected by contacting the bisulfite ion treated target gene sequence, following exposure to alkaline conditions, with an oligonucleotide that selectively hybridizes to a nucleotide sequence of the target gene that either contains uracil residues or that lacks uracil residues, but not both, and detecting selective hybridization (or the absence thereof) of the oligonucleotide. 
     The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention. 
     EXAMPLES 
     Example 1 
     Analysis of Methylation 
     DNA was extracted according to standard protocols known to those of skill in the art (see, e.g., Sambrook et al., Molecular Cloning: a Laboratory Manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Plainview, N.Y., 1998, herein incorporated by reference). Briefly, methylation patterns in the CpG island of the genes were determined by chemical modification of genomic DNA with sodium bisulfite and subsequent methylation-specific PCR (MSP) according to protocols known to those of skill in the art (see, e.g. Belinsky Steven A and Palmisano William A, WO0218649). Briefly, 0.5 μg of DNA was denatured by NaOH and modified by sodium bisulfite. DNA samples were then purified using the EZ DNA Methylation Kit™ from Zymo Research, precipitated with ethanol, and resuspended in H 2 O. To facilitate MSP analysis on DNA retrieved from formalin-fixed, paraffin embedded tissue, DNA was first amplified with flanking PCR primers that amplify bisulfite-modified DNA but do not preferentially amplify methylated or unmethylated DNA. The resulting fragment was used as a template for the MSP reaction. Primer sequences and the corresponding annealing temperature are indicated in Table 4. 
                                                                           TABLE 4                                   seq id           primer   product   length   filter Tm   sequence   no.                                ASK flank up   150   22   58.6   5′ TTA GAA GGY GGG AAT AAT TTT G 3′   53           ASK flank down       22   57.7   5′ TCA ATC TCA AAC CC R  AAC TCT C 3′   54       ASK Ms   121   16   60.0   5′ GGT GAC GGG CGG GGT 3′   55       ASK Mas       20   60.6   5′ AAA CCC GAA CTC TCG ATC CG 3′   56       ASK Us   128   20   61.1   5′ TTT TGG TGA TGG GTG GGG TT 3′   57       ASK Uas       23   60.3   5′ CTC AAA CCC AAA CTC TCA ATC CA 3′   58               TM4SF11 flank up   114   24   56.7   5′ GTA TTT GG Y  GTT TTA GGT TTT TAG 3′   59       TM4SF11 flank down       20   55.7   5′ CCC CTC CAA C R A TAA ATA CC 3′   60       TM4SF11 Ms   91   25   60.2   5′ TTT TAG TTT CGA CGT TTT TTG TAG C3′   61       TM4SF11 Mas       22   61.0   5′ CAA CGA TAA ATA CCG ACT CCC G 3′   62       TM4SF11 Us   96   27   59.9   5′ GGTTTTTAGTTTTGATGTTTTTGTAGT 3′   63       TM4SF11 Uas       24   60.4   5′ TCCAACAATAAATACCAACTCCCA 3′   64               NDP flank up   110   21   54.4   5′ GGT GGG TAG AGG TTG AGT TTT 3′   65       NDP flank down       26   55.6   5′ CCA TTA CAA TCA TAT ATC AAT CAA AC 3′   66       NDP Ms   91   23   59.6   5′ AGG TTG AGT TTT CGA TAA CGA GC 3′   67       NDP Mas       25   60.9   5′ CAT ATA TCA ATC AAA CGC GTA CGA CCG 3′   68       NDP Us   99   28   61.0   5′ GGT AGA GGT TGA GTT TTT GAT PAT GAG T 3′   69       NDP Uas       28   59.3   5′ AAT CAT ATA TCA ATC AAA CAT ACA ACC A 3′   70               RUNX3 flank up   157   20   57.8   5′ TAG TGG GGA TGG GAG GTG TT 3′   71       RUNX3 flank down       19   54.8   5′ CCC CAA AAC CCA AAT AAA A 3′   72       RUNX3 Ms   97   21   60.0   5′ ATG GGA GGT GTT CGA GAC GTC 3′   73       RUNX3 Mas       20   60.3   5′ AAC GCA TCC AAA ACG AAA CG 3′   74       RUNX3 Us   97   23   61.2   5′ GGA TGG GAG GTG TTT GAG ATG TT 3′   75       RUNX3 Uas       26   60.8   3′ CTA CAA AAC ACA TCC AAA ACA AAA CA 5′   76               C11orf2 flank up   156   19   57.6   5′ GGG TTT GGA TTT GGG GAT T 3′   77       C11orf2 flank down       22   57.2   5′ CAA ATC AAT C R A ATC CAA AAA A 3′   78       C11orf2 Ms   105   19   62.9   5′ GGG GAG GTT TCG GAG CGT C 3′   79       C11orf2 Mas       19   62.8   5′ CAA AAA ATC GAA CCC CGC G 3′   80       C11orf2 Us   112   22   62.8   5′ GAG GGG GAG GTT TTG GAG TGT T 3′   81       C11orf2 Uas       23   62.2   5′ AAT CCA AAA AAT CAA ACC CCA CA 3′   82       ACTN1 flank up   121   20   57.5   5′ GAG GTG GGG TGT TGG GTT AT 3′   83               ACTN1 flank down       19   57.9   5′ CCC CCA AAA AAA CCT ACC C 3′   84       ACTN1 Ms   91   18   61.0   5′ TAG GCG TTT GGC GGA AGC 3′   85       ACTN1 Mas       18   60.1   5′ ACC TAC CCG CCA ACG ACG 3′   86       ACTN1 Us   102   24   60.6   5′ GGG TTA TAG GTG TTT GGT GGA AGT 3′   87       ACTN1 Uas       23   60.2   5′ AAA AAA CCT ACC CAC CAA CAA CA 3′   88               CGI-38 flank up   160   24   56.9   5′ GAG T Y G TTT GGG TTG TAG TTT TAT 3′   89       CGI-38 flank down       28   56.1   5′ ATC TAA ATC TCC TAT AAA CTT CTA CCT C 3′   90       CGI-38Ms   111   19   61.0   5′ TCG GGA GTC GGT AGG GAG C 3′   91       CGI-38 Mas       25   59.7   5′ CTC GCG ACT ACT CCT AAA ATA TAC G 3′   92       CGI-38 Us   121   24   60.6   5′ TTT ATT TGG GAG TTG GTA GGG AGT 3′   93       CGI-38 Uas       30   59.7   5′ TCT ACC TCA CAA CTA CTC CTA AAA TAT ACA 3′   94               DEK flank up   131   20   56.3   5′ GAA GT Y  GTT TTT GGG GAT TG 3′   95       DEK flank down       19   56.0   5′ ATC CTC CTA CTC CC R  CAA A 3′   96       DEK Ms   105   20   62.0   5′ GGA TTG AGC GTT GCG GTT TC 3′   97       DEK Mas       19   61.4   5′ CCG CAA ACA AAA CCG AAC G 3′   98       DEK Us   110   22   59.8   5′ GGG GAT TGA GTG TTG TGG TTT T 3′   99       DEK Uas       22   59.5   5′ CTC CCA CAA ACA AAA CCA AAC A 3′   100               HDGF flank up   147   25   55.4   5′ GA Y  GTT TTT AGG GTT ATT TTT TAT A 3′   101       HDGF flank down       25   55.6   5′ TCC ACA AAT ATT TAC TAA ACA CCC 3′   102       HDGF Ms   115   26   59.0   5′ GTT ATT TTT TAT ACG GTA AGT ACG GC 3′   103       HDGF Mas       20   59.6   5′ ACC CGC GAT TCT TAA CAA CG 3′   104       HDGF Us   124   29   60.3   5′ AGG GTT ATT TTT TAT ATG GTA AGT ATG GT 3′   105       HDGF Uas       26   60.1   5′ CTA AAC ACC CAC AAT TCT TAA CAA CA 3′   106               HPSE flank up   133   19   56.3   5′ GGY GGG AGG AAG TGT TAG A 3′   107       HPSE flank down       21   57.6   5′ CCC CAA AAA CAA CAA CAT CAA 3′   108       HPSE Ms   112   24   60.4   5′ TTA GAG TTT TCG ATT TTT CGT TGC 3′   109       HPSE Mas       22   60.0   5′ AAC AAC AAC ATC AAC GAC GAC G 3′   110       HPSE Us   121   29   61.4   5′ AAG TGT TAG AGT TTT TGA TTT TTT GTT GT 3′   111       HPSE Uas       26   61.8   5′ CAA AAA CAA CAA CAT CAA CAA CAA CA 3′   112               TNFRFS10B flank up   122   20   57.3   5′ GTT TTT GGG AAG GGG AGA AG 3′   113       TNFRSF10B flank       28   56.3   5′ AAT TAA AAA AAA CAC TTA AAA AAT TAA C 3′   114       down       TNFRSF10B Ms   81   22   60.8   5′ GAT TAA GAC GCG TTT GGA AAG C 3′   115       TNFRSF10B Mas       20   61.2   5′ ATT AAC GCC TCC CGA AAT CG 3′   116       TNFRSF10B Us   93   28   62.8   5′ GGA GAA GAT TAA GAT GTG TTT GGA AAG T 3′   117       TNFRSF10B Uas       26   61.5   5′ TAA AAA ATT AAC ACC TCC CAA AAT CA 3′   118               TTK flank up   134   25   56.5   5′ TTA AAT TGG AAA GAT TAG GAA AGT T 3′   119       TTK flank down       18   57.1   5′ TCA AAC TAA ACC C R C CCC 3′   120       TTK Ms   104   23   61.3   5′ ATT AGG AAA GTT CGT TTA CGG GC 3′   121       TTK Mas       20   62.6   5′ CGA AAA AAC CTA CGA CCG CG 3′   122       TTK Us   111   28   62.5   5′ GAA AGA TTA GGA AAG TTT GTT TAT GGG T 3′   123       TTK Uas       22   61.2   5′ CCC GAA AAA ACC TAC AAC CAC A 3′   124               HEC flank up   151   19   57.4   5′ TTG GGG TGA Y  GTA GTT GGG 3′   125       HEC flank down       19   58.0   5′ CCA AAT CCT TCC TC R  ACC C 3′   126       HEC Ms   99   22   61.5   5′ CGT AGT TGG GCG CGA TTA GTA C 3′   127       HEC Mas       18   61.6   5′ TCT CCG CCG ACG CTA ACG 3′   128       HEC Us   113   27   60.3   5′ GGT GAT GTA GTT GGG TGT GAT TAG TAT 3′   129       HEC Uas       27   60.7   5′ ATT TAA AAT TCT CCA CCA ACA CTA ACA 3′   130               MYBL2 flank up   139   23   57.3   5′ GGT TTT  Y GT TAT GTG GGA TAT TT 3′   131       MYBL2 flank down       19   57.6   5′ ACC CAA ACC CTC CAA AAC C 3′   132       MYBL2 Ms   99   22   60.9   5′ TTG GGT CGT TTC GGA TTG ATA C 3′   133       MYBL2 Mas       23   61.5   5′ CCG ACT ACA AAA CAA AAA CGA CG 3′   134       MYBL2 Us   104   24   59.9   5′ TTT TGG GTT GTT TTG GAT TGA TAT 3′   135       MYBL2 Uas       26   60.0   5′ AAA CCA ACT ACA AAA CAA AAA CAA CA 3′   136               POLR3D flank up   149   24   57.8   5′ TTT AGG TAA TAT GT Y  GGA AGG AAA 3′   137       POLR3D flank down       24   57.4   5′ CCC TAA AAC  R AA TAA AAA AAA AAC 3′   138       POLR3D Ms   106   22   59.9   5′ TTT AGT ACG TCG GGA GGG TTT C 3′   139       POLR3D Mas       23   60.4   5′ AAC GAA TAA AAA AAA AAC GAC CG 3′   140       POLR3D Us   113   25   59.8   5′ GAG TTT AGT ATG TTG GGA GGG TTT T 3′   141       POLR3D Uas       27   59.6   5′ CTA AAA CAA ATA AAA AAA AAA CAA CCA 3′   142               TK1 flank up   110   24   57.7   5′ TTT TAG GTT TTT TTA GTT TTT GGG 3′   143       TK1 flank down       20   57.4   5′ CAT AAA ACC AAT CAA CRC CC 3′   144       TK1 Ms   91   23   60.8   5′ TTT AGT TTT TGG GCG TAC GTT TC 3′   145       TK1 Mas       17   59.4   5′ CAA TCA ACG CCC GAC CG 3′   146       TK1 Us   100   27   60.8   5′ TTT TTT TAG TTT TTG GGT GTA TGT TTT 3′   147       TK1 Uas       22   61.0   5′ AAA ACC AAT CAA CAC CCA ACC A 3′   148               TRIP13 flank up   114   22   56.5   5′ TTA TYG TTT TTT GGT TTT GGT T 3′   149       TRIP13 flank down       20   56.0   5′ ACA AAA CCA CTT CCT ACC  R C 3′   150       TRIP13 Ms   93   20   61.8   5′ GGT TTT GGT TGG TCG TTC GC 3′   151       TRIP13 Mas       18   62.4   5′ CTT CCT ACC GCG ACC CCG 3′   152       TRIP13 Us   99   23   60.9   5′ TTT GGT TTT GGT TGG TTG TTT GT 3′   153       TRIP13 Uas       21   61.0   5′ CCA CTT CCT ACC ACA ACC CCA 3′   154               BARD1 flank up   105   25   56.6   5′ GTT TAG TTT TTA GGT TTY GTT TTT T 3′   155       BARD1 flank down       24   57.5   5′ AAA CAA AAC AAA AC R  ACT AAA ACC 3′   156       BARD1 Ms   81   22   60.2   5′ GGT TTC GTT TTT TCG GTT AAG C 3′   157       BARD1 Mas       21   60.5   5′ ACG ACT AAA ACC GAA ATC CCG 3′   158       BARD1 Us   89   27   60.4   5′ TTT TAG GTT TTG TTT TTT TGG TTA AGT 3′   159       BARD1 Uas       24   59.6   5′ AAA ACA ACT AAA ACC AAA ATC CCA 3′   160               FANCG flank up   133   26   58.5   3′ GTT TTT AGT TAT YGT TTT TTG GAA AT 5′   161       FANCG flank down       21   59.1   3′ CCC CAA ATC CTC CTA AAT TCC 5′   162       FANCG Ms   95   23   64.3   3′ TTG GAA ATA TTA TTC GTC GGG GC 5′   163       FANCG Mas       19   65   3′ CCG CTT CCA CCG AAA ACC G 5′   164       FANCG Us   108   28   64.8   3′ GTT TTT TGG AAA TAT TAT TTG TTG GGG T 5′   165       FANCG Uas       27   64.2   3′ CTA AAT TCC CTC TTC GAC CTA AAA CCT 5′   166               SMPD2 flank up       22   55.3   5′ GGT TGG GTT TTT TTT TAA TTT T 3′   167       SMPD2 flank down       21   56.5   5′ TTT TCC CTA AAA ATC CRA AAA 3′   168       SMPD2 Ms       20   60   5′ GCG TTT GTT GTT GGG TCG TC 3′   169       SMPD2 Mas       19   59.4   5′ CCC GAA TAA ACG ACT CCC G 3′   170       SMPD2 Us       23   59.3   5′ TTT GTG TTT GTT GTT GGG TTG TT 3′   171       SMPD2 Uas       21   60.8   5′ CCC CCA AAT AAA CAA CTC CCA 3′   172                    
All PCRs were performed with controls for unmethylated alleles (DNA from normal lymphocytes), methylated alleles [normal lymphocyte DNA treated in vitro with SssI methyltransferase (New England Biolabs)], and a control without DNA. Ten μl of each MSP reaction were directly loaded onto nondenaturing 6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination. Primer sequences for the first round PCR are indicated as flank up and flank down. Primer sequences for the subsequent unmethylated reaction are indicated as Us (sense) and Uas (antisense) and for the methylated reaction Ms (sense) and Mas (antisense).
 
     Example 2 
     Specimens 
     Specimens comprised normal tubae (n=8; derived from women with an extra-uterine pregnancy), serous borderline tumors (SBT n=36 of which 24 were paraffin-embedded samples, and 12 were fresh frozen) and grade I and grade III serous carcinomas(SCA n=75, of which 46 were paraffin-embedded samples, and 26 were fresh frozen). Tumor material was retrieved from the tumor bank of the department of Pathology, University Medical Centre Leiden (see JCO 2005 Sieben et al) and from the department of Pathology, University Hospital Maastricht. Tubae were. 
     Cell line material was obtained from Ovar3, T29 and T29K cell lines. 
     Example 3 
     Promoter hypermethylation was examined in all specimen. Tables 5 and 6 show the results obtained and the SCA grading for each of the subjects. 
     
       
         
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
               
             
               
               
               
             
           
               
                 TABLE 5 
               
               
                   
               
               
                 Tubae 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 sample 
                 RASSF1A 
                 RASSF2A 
                 WIF1 
                 APC 
                 SFRP1 
                 SFRP2 
                 SFRP4 
                 SFRP5 
                 MGMT 
               
               
                   
               
               
                 T1 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T2 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 T3 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T4 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                 T5 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T6 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T7 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 T8 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                   
               
             
          
           
               
                   
                 sample 
                 BRCA1 
                 MLH1 
                 FANCF 
                 p14 
                 p16 
                 CHFR 
                 GATA4 
                 GATA5 
                 HLTF 
               
               
                   
                   
               
               
                   
                 T1 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T2 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
                 U 
                 U 
               
               
                   
                 T3 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T4 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T5 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T6 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T7 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 T8 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                   
                   
               
             
          
           
               
                   
                 gene 
                 frequency 
               
               
                   
                   
               
               
                   
                 RASSF1A 
                 0/8 
               
               
                   
                 RASSF2A 
                 0/8 
               
               
                   
                 WIF1 
                 0/8 
               
               
                   
                 APC 
                 1/8 (13%) 
               
               
                   
                 SFRP1 
                 0/8 
               
               
                   
                 SFRP2 
                 0/8 
               
               
                   
                 SFRP4 
                 3/8 (38%) 
               
               
                   
                 SFRP5 
                 0/8 
               
               
                   
                 MGMT 
                 1/8 (13%) 
               
               
                   
                 BRCA1 
                 1/8 (13%) 
               
               
                   
                 MLH1 
                 0/8 
               
               
                   
                 FANCF 
                 0/8 
               
               
                   
                 p14 
                 0/8 
               
               
                   
                 p16 
                 2/8 (25%) 
               
               
                   
                 CHFR 
                 0/8 
               
               
                   
                 GATA4 
                 2/8 (25%) 
               
               
                   
                 GATA5 
                 0/8 
               
               
                   
                 HLTF 
                 0/8 
               
               
                   
                   
               
               
                   
                 U = unmethylated; 
               
               
                   
                 M = methylated 
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 6 
               
               
                   
               
               
                 (below) MSP Metascore 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                   
                   
                   
                   
                   
                   
                   
                   
                 CGI- 
                   
                   
                   
                   
                   
                   
                   
               
               
                 sample 
                 diagnosis 
                 grade 
                 NDP 
                 TM4SF11 
                 RUNX3 
                 TNFRSF10B 
                 DEK 
                 38 
                 HEC 
                 MYBL2 
                 TTK 
                 BARD1 
                 ACTN1 
                 C11ORF2 
                 SMPD2 
               
               
                   
               
               
                 T1 
                 tuba 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T2 
                 tuba 
                   
                 u 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T3 
                 tuba 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T4 
                 tuba 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
               
               
                 T5 
                 tuba 
                   
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T6 
                 tuba 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T7 
                 tuba 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 T8 
                 tuba 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                 529 
                 SBT 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 530 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 U 
               
               
                 531 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                 533 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 535C 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 536 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 536A 
                 SBT 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 537A 
                 SBT 
                   
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 537B 
                 SBT 
                   
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 538 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 539A 
                 SBT 
                   
                 M 
                 U 
                 M 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 540 
                 SBT 
                   
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 541A 
                 SBT 
                   
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 542 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 U 
               
               
                 550C 
                 SBT 
                   
                 M 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 584 
                 SBT 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 592A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 594A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 596A 
                 SBT 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 597A 
                 SBT 
                   
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                 598A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 599A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 600A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 601A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 602A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 615-1 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 615-2 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
               
               
                 V2 
                 SBT 
                   
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V7 
                 SBT 
                   
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V11 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V61 
                 SBT 
                   
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V61A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V81 
                 SBT 
                   
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V82 
                 SBT 
                   
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V82A 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V110 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V150 
                 SBT 
                   
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V195 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V220 
                 SBT 
                   
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
               
               
                 V244 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
                 M 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V245 
                 SBT 
                   
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 544B 
                 SCA 
                 II 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 545A 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 GR 
                 GR 
                 GR 
                 GR 
                 U 
                 GR 
                 GR 
                 GR 
                 U 
                 U 
               
               
                 546 
                 SCA 
                 III 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
               
               
                 547 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 548 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
               
               
                 549A 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 549C 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 M 
               
               
                 551A 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 551B 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 552 
                 SCA 
                 II 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 553 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 554 
                 SCA 
                 III 
                 M 
                 M 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 555 
                 SCA 
                 III 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 556 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 557C 
                 SCA 
                 I 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 558 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 559 
                 SCA 
                 ? 
                 M 
                 U 
                 M 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 560 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 561A 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 561B 
                 SCA 
                 I 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 562 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 563 
                 SCA 
                 III 
                 M 
                 U 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 564B 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 565 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 566 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 567 
                 SCA 
                 ? 
                 U 
                 M 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 568A 
                 SCA 
                 ? 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
               
               
                 569 
                 SCA 
                 III 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 570A 
                 SCA 
                 II 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 571A 
                 SCA 
                 III 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 M 
                 M 
                 U 
                 M 
               
               
                 572A 
                 SCA 
                 II 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 572B 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 573 
                 SCA 
                 ? 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 574 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 575 
                 SCA 
                 II 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                 576 
                 SCA 
                 I 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 578 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 579 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 580 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 581 
                 SCA 
                 II 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 582 
                 SCA 
                 ? 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 583 
                 SCA 
                 ? 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 585 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                 586 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 587 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 588 
                 SCA 
                 III 
                 GR 
                 GR 
                 GR 
                 U 
                 GR 
                 GR 
                 U 
                 U 
                 GR 
                 GR 
                 GR 
                 GR 
                 GR 
               
               
                 589 
                 SCA 
                 II 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 591 
                 SCA 
                 ? 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 593 
                 SCA 
                 III 
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                 595 
                 SCA 
                 II 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V1 
                 SCA 
                 I 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V27 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V40 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                 V46 
                 SCA 
                 III 
                 U 
                 U 
                 M 
                 M 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V73 
                 SCA 
                 ? 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V122 
                 SCA 
                 II 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V132 
                 SCA 
                 I 
                 U 
                 U 
                 M 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V143 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V151 
                 SCA 
                 III 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V154 
                 SCA 
                 III 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V171 
                 SCA 
                 I 
                 U 
                 U 
                 M 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V176 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V179 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V180 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V181 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                 V187 
                 SCA 
                 III 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V221 
                 SCA 
                 I 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V229 
                 SCA 
                 I 
                 M 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V239 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V240 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V241 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                 V242 
                 SCA 
                 III 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V243 
                 SCA 
                 III 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V246 
                 SCA 
                 I 
                 GR 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                 V249 
                 SCA 
                 I 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V249A 
                 SCA 
                 I 
                 U 
                 U 
                 M 
                 U 
                 U 
                 GR 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                 V251 
                 SCA 
                 III 
                 M 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                   
               
             
          
           
               
                   
                 sample 
                 TK1 
                 HDGF 
                 POLR3D 
                 FANCG 
                 TRIP13 
                 HPSE 
                 ASK 
               
               
                   
                   
               
               
                   
                 T1 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 gene 
                 tuba 
                 SBT 
               
               
                   
                 T2 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 NDP 
                 3/8 (38%) 
                 12/36 (33%) 
               
               
                   
                 T3 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 TM4SF11 
                 0/8 
                 1/36 (2%) 
               
               
                   
                 T4 
                 M 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 RUNX3 
                 0/8 
                  9/36 (25%) 
               
               
                   
                 T5 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 TNFRSF10B 
                 1/8 (13%) 
                 16/36 (44%) 
               
               
                   
                 T6 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 DEK 
                 1/8 (13%) 
                 2/36 (6%) 
               
               
                   
                 T7 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 CGI-38 
                 1/8 (13%) 
                 3/36 (8%) 
               
               
                   
                 T8 
                 U 
                 U 
                 M 
                 U 
                 M 
                 U 
                 M 
                 HEC 
                 2/8 (25%) 
                  8/35 (23%) 
               
               
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 MYBL2 
                 4/8 (50%) 
                  7/36 (19%) 
               
               
                   
                 529 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 TTK 
                 0/8 
                 0/36 
               
               
                   
                 530 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 BARD1 
                 1/8(13%) 
                 2/36 (6%) 
               
               
                   
                 531 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 U 
                 ACTN1 
                 1/8 (13%) 
                  8/36 (22%) 
               
               
                   
                 533 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 C11ORF2 
                 0/8 
                 0/34 
               
               
                   
                 535C 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 SMPD2 
                 2/8 (25%) 
                 2/35 (%)  
               
               
                   
                 536 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 TK1 
                 1/8 (13%) 
                 3/36 (8%) 
               
               
                   
                 536A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 HDGF 
                 0/8 
                 0/36 
               
               
                   
                 537A 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 POLR3D 
                 2/8 (25%) 
                 0/32 
               
               
                   
                 537B 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 FANCG 
                 0/8 
                 0/31 
               
               
                   
                 538 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 TRIP13 
                 1/8 (13%) 
                 0/36 
               
               
                   
                 539A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 HPSE 
                 0/8 
                 1/36 (3%) 
               
               
                   
                 540 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 ASK 
                 1/8 (13%) 
                 1/35 (3%) 
               
               
                   
                 541A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 542 
                 U 
                 U 
                 GR 
                 GR 
                 U 
                 U 
                 U 
               
               
                   
                 550C 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 584 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 592A 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
               
               
                   
                 594A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 596A 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 597A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 598A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 599A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 600A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 601A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 602A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 615-1 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 615-2 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 M 
                 U 
               
               
                   
                 V2 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V7 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
               
               
                   
                 V11 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V61 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
               
               
                   
                 V61A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V81 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V82 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V82A 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V110 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V150 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 V195 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V220 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V244 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V245 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 544B 
                 U 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
               
               
                   
                 545A 
                 GR 
                 GR 
                 GR 
                 GR 
                 GR 
                 GR 
                 GR 
               
               
                   
                 546 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 547 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 548 
                 M 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
               
               
                   
                 549A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 549C 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 551A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 551B 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 552 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 553 
                 U 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
               
               
                   
                 554 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 555 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 556 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 557C 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 558 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 559 
                 U 
                 U 
                 U 
                 GR 
                 U 
                 U 
                 U 
               
               
                   
                 560 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 561A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 561B 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 562 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 563 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 564B 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 565 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 566 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 567 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 568A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 569 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 570A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 571A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 572A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 572B 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 573 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 574 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 575 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 576 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 578 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 579 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 580 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 581 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 582 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 583 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 585 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 586 
                 U 
                 GR 
                 GR 
                 GR 
                 U 
                 U 
                 GR 
               
               
                   
                 587 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 588 
                 GR 
                 GR 
                 GR 
                 GR 
                 U 
                 GR 
                 GR 
               
               
                   
                 589 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 591 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 593 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 595 
                 M 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V1 
                 U 
                 U 
                 U 
                 M 
                 M 
                 U 
                 U 
               
               
                   
                 V27 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V40 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V46 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V73 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V122 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 V132 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 M 
               
               
                   
                 V143 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 V151 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                   
                 V154 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V171 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V176 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 M 
               
               
                   
                 V179 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V180 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V181 
                 U 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
               
               
                   
                 V187 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V221 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V229 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V239 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V240 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V241 
                 U 
                 U 
                 M 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V242 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V243 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V246 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V249 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V249A 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                 V251 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
                 U 
               
               
                   
                   
               
               
                   
                 M = methylated; 
               
               
                   
                 U = unmethylated; 
               
               
                   
                 GR = no results 
               
             
          
         
       
     
     In ovarian cell lines the genes NDP, TM4SF11, RUNX3, TNFRSF10B, DEK, HEC, CGI-38, MYBL2 were found to be hypermethylated, whereas TTK, BARD1, ACTN1, C11ORF2, SMPD2, TK1, HDGF, POLR3D, FANCG, TRIP13, HPSE, ASK were non-methylated. 
     From the genes methylated in cell lines, TM4SF11 and RUNX3 were non-methylated in the Tubae test population, whereas TNFRSF10B, DEK, and CGI-38 were methylated only in one out of the eight (13%). NDP, HEC, MYBL2 were methylated in more than one out of the eight (&gt;13%) specimen of the Tubae test population. 
     The genes TNFRSF10B, RUNX3, TM4SF11, ACTN1 and FANCG were found to be methylated in a higher degree in SBT and/or SCA when compared to their methylation status in Tubae. 
     Of the genes TTK, BARD1, ACTN1, C11ORF2, SMPD2, TK1, HDGF, POLR3D, FANCG, TRIP13, HPSE, ASK which were non-methylated in cell-lines, two genes SMPD2 and POLR3D appeared to be methylated in 2 out of the 8 Tubae specimen. TTK, C11ORF2, HDGF, FANCG and HPSE were unmethylated in all of the 8 Tubae. The remainder genes were methylated in 1 out of the 8 Tubae. 
     The genes ACTN1, HDGF, FANCG and HPSE were found to be methylated in a higher degree in SBT and/or SCA when compared to their methylation status in Tubae. 
     REFERENCES 
     The disclosure of each reference cited is expressly incorporated herein.
     Reeves et al., U.S. Pat. No. 6,596,493   Sidransky, U.S. Pat. No. 6,025,127   Sidransky, U.S. Pat. No. 5,561,041   Nelson et al., U.S. Pat. No. 5,552,277   Herman, et al., U.S. Pat. No. 6,017,704   Baylin et al, U.S. Patent Application Publication No. 2003/0224040 A1   Belinsky et al., U.S. Patent Application Publication No. 2004/0038245 A1   Sidransky, U.S. Patent Application Publication No. 2003/0124600 A1   Sidransky, U.S. Patent Application Publication No. 2004/0081976 A1   Sukumar et al., U.S. Pat. No. 6,756,200 B2   Herman et al., U.S. Patent Application Publication No. 2002/0127572 A1
Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.